Contact us

ESH Video

#ESHLYMPHOMA2024 PROGRAMME HIGHLIGHT: ROUNDTABLE 2 ON NOVELTIES IN MARGINAL ZONE LYMPHOMA AND WALDENSTRÖM MACROGLOBULINEMIA

4^th How to Diagnose and Treat

LYMPHOMA

November 1-3, 2024

Stockholm, Sweden

#ESHLYMPHOMA2024

Chairpersons: Christian Buske (Ulm), Michael Crump (Toronto),
Gilles Salles (New York), Catherine Thieblemont (Paris)

PROGRAMME HIGHLIGHT: ROUNTABLE 2

Novelties in marginal zone lymphoma and
Waldenström macroglobulinemia

Chairs: Christian Buske (Ulm), Catherine Thieblemont (Paris)

The many faces of Splenic and nodal marginal zone lymphoma
by Francesco Bertoni (Bellinzona)

High-risk marginal zone lymphoma
by Luca Arcaini (Pavia)

New era in marginal zone lymphomas: IBTK new generation, bispecifics, CAR-T
by Catherine Thieblemont (Paris)

Update on Waldenström Macroglobulinemia
by Christian Buske (Ulm)

(followed by discussion)


Saturday, November 2, 2024 / 14:20-15:30

About the Conference:

ESH How to Diagnose and Treat meetings are disease-specific meetings that address state-of-the-art diagnostic and clinical management.

They are based on the presentation and analysis of real clinical cases. Voting technology is used as a self-evaluation tool and to increase scientific interaction.

CONFERENCE MAIN SCIENTIFIC TOPICS

• Aggressive B cell lymphomas: Diffuse large B cell lymphoma,
High grade B cell lymphoma and Burkitt
• Mantle cell lymphoma
• Challenging T cell lymphomas
• Mantle Cell lymphoma: Optimal cellular therapy for
relapsed disease CAR T vs AlloSCT
• Diffuse large B cell lymphoma
• Diffuse large B-cell lymphoma: Immune based therapy
• Novelties in marginal zone lymphoma and Waldenström macroglobulinemia
• What is the optimal regimen for advanced Hodgkin’s lymphoma?
• Chronic lymphocytic leukemia
• Follicular Lymphoma
• Bispecific VS Car-T
• Immune environment in Hodgkin’s lymphoma

CALL FOR ABSTRACTS & CLINICAL CASES
Deadline:  August 19^th, 2024

With the support of*:


Major Conference Partner
*******

Level 1 Conference Partners
*******

*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.